Valneva SE (VALN) Cash & Current Investments (2019 - 2026)
Valneva SE (VALN) posted quarterly Cash & Current Investments of $119.8 million for Q1 2026, down 31.19% year-on-year from $174.1 million in Q1 2025, and down 4.0% on a QoQ basis from $124.8 million in Q4 2025.
Valneva SE (VALN) Cash & Current Investments (2019 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Cash & Current Investments for 8 consecutive years, with $119.8 million the latest figure, recorded in Q1 2026.
- Quarterly Cash & Current Investments fell 31.19% year-over-year to $119.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.8 million (down 31.19% YoY) and the FY2025 annual result came in at $124.8 million, down 35.32% from the prior year.
- Cash & Current Investments eased to $119.8 million in Q1 2026 per VALN's latest filing, from $124.8 million in the prior quarter.
- Over the last five years, Cash & Current Investments for VALN reached as high as $382.6 million in Q2 2022 and fell as low as $119.8 million in Q1 2026.
- A 5-year average of $218.2 million and a median of $192.9 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 716230.0% — and 2023, when it slumped 55.61%.
- Year by year, Cash & Current Investments stood at $326.1 million in 2022, then sank by 55.61% to $144.7 million in 2023, then soared by 33.29% to $192.9 million in 2024, then sank by 35.32% to $124.8 million in 2025, then dropped by 4.0% to $119.8 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $119.8 million, $124.8 million, and $163.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Valneva SE | 839.18 Mn | 719.39 Mn | 5.38 Mn | 119.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.79 Mn |
| Dec 31, 2025 | 124.78 Mn |
| Sep 30, 2025 | 163.25 Mn |
| Jun 30, 2025 | 185.05 Mn |
| Mar 31, 2025 | 174.10 Mn |
| Dec 31, 2024 | 192.91 Mn |
| Sep 30, 2024 | 177.90 Mn |
| Jun 30, 2024 | 149.54 Mn |
| Mar 31, 2024 | 201.01 Mn |
| Dec 31, 2023 | 144.74 Mn |
| Sep 30, 2023 | 194.88 Mn |
| Jun 30, 2023 | 232.61 Mn |
| Mar 31, 2023 | 289.59 Mn |
| Dec 31, 2022 | 326.06 Mn |
| Sep 30, 2022 | 297.05 Mn |
| Jun 30, 2022 | 382.61 Mn |
| Mar 31, 2022 | 354.20 Mn |
| Dec 31, 2021 | 45,518.17 |
| Sep 30, 2021 | 282.15 Mn |
| Jun 30, 2021 | 375.30 Mn |